Back to Search Start Over

EyePoint announces permanent J-Code for intracameral steroid

Source :
Ophthalmology Times. November 1, 2018, Vol. 43 Issue 18, 24
Publication Year :
2018

Abstract

EYEPOINT Pharmaceuticals announced the Centers for Medicare and Medicaid Services (CMS) has assigned a specific/permanent reimbursement J-code for dexamethasone intraocular suspension 9% (DEXYCU), the first and only FDA-approved, single-dose, sustained-release, [...]

Details

Language :
English
ISSN :
0193032X
Volume :
43
Issue :
18
Database :
Gale General OneFile
Journal :
Ophthalmology Times
Publication Type :
Periodical
Accession number :
edsgcl.568370742